Shares of Can-Fite Biopharma Ltd (NASDAQ:CANF) have received a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy recommendation. Can-Fite Biopharma’s rating score has improved by 66.7% in the last 90 days as a result of various analysts’ upgrades and downgrades.

Analysts have set a twelve-month consensus target price of $29.99 for the company and are expecting that the company will post ($1.94) EPS for the current quarter, according to Zacks. Zacks has also given Can-Fite Biopharma an industry rank of 83 out of 256 based on the ratings given to related companies.

Separately, HC Wainwright reiterated a “buy” rating on shares of Can-Fite Biopharma in a research note on Tuesday, March 26th.

Shares of NASDAQ CANF opened at $3.22 on Monday. Can-Fite Biopharma has a 52-week low of $2.91 and a 52-week high of $25.95.

Can-Fite Biopharma (NASDAQ:CANF) last announced its quarterly earnings results on Thursday, March 28th. The company reported ($0.18) earnings per share (EPS) for the quarter. The firm had revenue of $0.29 million for the quarter.

Can-Fite Biopharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. The company's lead drug candidate is CF101, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis.

Featured Story: What is Green Investing?

Get a free copy of the Zacks research report on Can-Fite Biopharma (CANF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Can-Fite Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.